Client Needs: Prioritize among 8 medical devices, pharmaceutical compounds and biologics, those with the highest probability for successful commercialization.

A regional biomedical research institute with early development stage technologies retained Strategy Inc. to determine which technologies would deliver the highest return. The institute's CEO and Senior management desired to prioritize limited resources and also wanted to use their influence to shine the limelight on those technologies slated for success. The analysis was further compounded by the fact that the portfolio included medical devices, pharmaceutical compounds and biologics. In addition, several of the technologies were at the earliest concept state while others ranged from completion of a prototype to two that had already obtained clinical data. The questions ranged from: What is the size of the total addressable market, to determining the clinical interest in each of the technologies, to rating the technologies over current methods. The methods used with this analysis allowed determination of those with the highest probability for successful commercialization in a MOST cost effective manner, for prioritization of winning technologies to deliver a roadmap for the client to accelerate return for the desired exits.

Strategy Inc. Proven Processes
Strategy Inc. determined the three technologies with the highest probability for successful commercialization, provided a timeline to first-in-man clinical data, and created a business based summary to support funding activities for each technology. The process followed the trademarked TechSelect process including in-person interviews of the principal investigators, competitive landscape analysis and identification of the total addressable market for each technology. The process can be used to analyze as few as three technologies, up to 25 technologies.

Strategy Inc. Generates Results
This analysis provided the regional based incubator / accelerator with the business based roadmap to prioritize limited resources and the ability to highlight those technologies slated for success. This process brings the desired acclaim and respect and supports capital campaigns for additional resources.

Other Projects for Similar Clients
Other projects that have been executed for similar clients with the desire to prioritize among numerous technologies include but are not limited to the following:

• Business Plan for an incubator based in Europe with 6 technologies in different orthopedic subspecialities. The CEO desired to accelerate the two with the highest potential return on investment, one with a short time to exit and the other with a longer time to market.


• Business Plan for an innovative medical device concept to treat rheumatoid arthritis, when prior clinical solutions included mostly medical management with TNF alpha inhibitors. The CEO desired to determine the embodiment of the technology that would have the most rapid adoption while still delivering optimal clinical results.


• TechSelect for a university-based incubator with three potential indications for use for an energy based dermatology technology. Full analysis showed that only one of the three indications for use would be accepted by the target market.